

References for CHF: A Quantitative Approach

BNP

1. Nieminen M, Bohm M, Cowie M, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. *Eur Heart J*. 2005;26:384-416.
2. Peacock WF, Cannon CM, Singer AJ, Hiestand BC. Considerations for initial therapy in the treatment of acute heart failure. *Crit Care*. 2015;19(399). doi:10.1186/s13054-015-1114-3.
3. Peacock WF. Congestive Heart Failure and Acute Pulmonary Edema. In: *Tintinalli's Emergency Medicine: A Comprehensive Study Guide, Seventh Edition*. ; 2011:405-415.
4. Thomas SS, Nohria A. Hemodynamic classifications of Acute Heart Failure and their Clinical Application. *Circ J*. 2012;76:278-286.
5. Nohria A, Lewis E, Stevenson LW. Medical Management of Advanced Heart Failure. *J Am Med Assoc*. 2002;287(5):628-640.
6. Fermann GJ, Collins SP. Initial Management of Patients with Acute Heart Failure. *Heart Fail Clin*. 2013;9(3):291-306. doi:10.1016/j.hfc.2013.04.004.
7. Collins SP, Storrow AB, Levy PD, et al. Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions: A Consensus Document from the SAEM/HFSA Acute Heart Failure Working Group. *Acad Emerg Med*. 2015;22(1):94-112. doi:10.1111/acem.12538.
8. Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart Failure Syndromes. *Ann Emerg Med*. 2007;49(5):627-669. doi:10.1016/j.annemergmed.2006.10.024.
9. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *The New England journal of medicine*. 2002; 347(3):161-7.
10. McCullough PA, Nowak RM, McCord J. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. *Circulation*. 2002; 106(4):416-22.
11. Maisel A, Hollander JE, Guss D. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. *Journal of the American College of Cardiology*. 2004; 44(6):1328-33.
12. Roberts E, Ludman AJ, Dworzynski K. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. *BMJ (Clinical research ed.)*. 2015; 350:h910.

13. Martindale JL, Wakai A, Collins SP. Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. *Academic emergency medicine*. 2016; 23(3):223-42.
14. Mueller C, Scholer A, Laule-Kilian K. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. *The New England journal of medicine*. 2004; 350(7):647-54.
15. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. *Circulation*. 2007; 115(24):3103-10.
16. Rutten JH, Steyerberg EW, Boomsma F. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. *American heart journal*. 2008; 156(1):71-7.
17. Schneider HG, Lam L, Lokuge A. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. *Annals of internal medicine*. 2009; 150(6):365-71.
18. Singer AJ, Birkhahn RH, Guss D. Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. *Circulation. Heart failure*. 2009; 2(4):287-93.
19. Boldanova T, Noveanu M, Breidhardt T. Impact of history of heart failure on diagnostic and prognostic value of BNP: results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study. *International journal of cardiology*. 2010; 142(3):265-72.
20. Meisel SR, Januzzi JL, Medvedovski M. Pre-admission NT-proBNP improves diagnostic yield and risk stratification – the NT-proBNP for Evaluation of dyspnoeic patients in the Emergency Room and hospital (BNP4EVER) study. *European heart journal. Acute cardiovascular care*. 2012; 1(2):99-108.
21. Steinhart BD, Levy P, Vandenberghe H. A Randomized Control Trial Using a Validated Prediction Model for Diagnosing Acute Heart Failure in Undifferentiated Dyspneic Emergency Department Patients-Results of the GASP4Ar Study. *Journal of cardiac failure*. 2017; 23(2):145-152.
22. Ray P, Arthaud M, Birolleau S, et al. Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. *J Am Geriatr Soc* 2005;53(4):643-8.
23. Mueller T, Gegenhuber A, Poelz W, et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. *Heart* 2005;91(5):606-12.

Exam or Text	Sensitivity	Specificity
Elevated JVP (>8cm)	48%	78%
Hepato Jugular Reflux	50%	75%

Bilateral Leg Edema	94%	10%
Orthopnea	66%	47%
S3	73%	42%
Rales	13%	94%

Sens and spec of tests

1. Gheorghide M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. *Eur J Heart Fail* 2010;12:423–433.
2. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA* 2005;294:1625–1633.
3. Nagueh SF. Non-invasive assessment of left ventricular filling pressure. *Eur J Heart Fail* 2018;20:38–48.
4. Mullens W, Borowski AG, Curtin RJ, Thomas JD, Tang WH. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. *Circulation* 2009;119:62–70. Parrinello G, Greene SJ, Torres D, Alderman M, Bonventre JV, Di Pasquale P, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, Butler J, Paterna S, Stevenson LW, Gheorghide M. Water and sodium in heart failure: a spotlight on congestion. *Heart Fail Rev* 2015;20:13–24.
5. Volpicelli G, Skurzak S, Boero E, Carpinteri G, Tengattini M, Stefanone V, Luberto L, Anile A, Cerutti E, Radeschi G, Frascisco MF. Lung ultrasound predicts well extravascular lung water but is of limited usefulness in the prediction of wedge pressure. *Anesthesiology* 2014;121:320–327.

Chest Xray findings poor sensitivity and specificity:

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. *J Am Coll Cardiol* 2013;62:147–239.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *JACC*. 2017;70(6):776-803.
3. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001

- Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. 2005;112:e154–e235.
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. *Eur Heart J* 2012;33:1787–847.

Volume overload

1. Zile MR, Bennett TD, St John Sutton M, et al. *Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous*
2. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. *Patterns of weight change preceding hospitalization for heart failure. Circulation* 2007;116:1549–54.
3. Fallick C, Sobotka PA, Dunlap ME. *Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail* 2011; 4: 669-75.
4. Clark AL, Coats AJ, Krum H, Katus HA, Mohacsi P, Salekin D, Schultz MK, Packer M, Anker SD. *Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle* 2017;8:549–556.
5. Loncar G, Springer J, Anker M, Doehner W, Lainscak M. *Cardiac cachexia: hicet nunc: "hic et nunc" - here and now. Int J Cardiol* 2015;201:e1–e12.
6. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L. *Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail* 2012;5:54–62.
7. Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O'Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ. *Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF trial. JACC Heart Fail* 2017;5:1–13.
8. Gheorghide M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, Filippatos G. *Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail* 2010;12:423–433.

9. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA*. 2005;294:1625-1633.

Bolus dose Nitroglycerin

1. Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, Dunne R, Zalenski R. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. *Ann Emerg Med*. 2007; 50(2): 144-52.
2. Nashed A, Allegra JR, Eskin B, Garg S. Prospective Trial of the Treatment of acute cardiogenic pulmonary edema with intravenous nitroglycerin boluses. *Ann Emerg Med*. 1997; 30:328.
3. Nashed AH, Allegra JR. Intravenous nitroglycerin boluses in treating patients with cardiogenic pulmonary edema. *Am J Emerg Med*. 1995; 13(5): 612-613.
4. Perlmutter MC, Cohen M, Stratton NS, Conterato M. Safety and Feasibility of prehospital treatment of acute pulmonary edema with intravenous bolus nitroglycerin. *Air Med J*. 2020; 39(4): 247-248.
5. Wilson SS, Kwiatkowski GM, Millis SR, Purakal JD, Mahajan AP, Levy P. Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure. *Am J Emerg Med*. 2017; 35(1): 126-131.

Diuretics

- Do not help and may cause further decline in the acute phase of APE (*J Am Soc Nephrol* 4:2, 1993) (*Am J Med* 96:3, 1994)
- Vasoconstrictor Response initially by IV furosemide (*Ann Intern Med* 1985; 103:1-6)
- Worsening of outcome when used in prehospital setting (*Chest*. 1987; 92:586-593)
- Head to head nitrites vs. furosemide (*Lancet* 1983;i:730-32)
- Typically requires high dose diuretics Indirect effects of diuretics may be counterproductive Increase neurohormonal activation 1,2 Reflex vasoconstriction, ↓ cardiac output 1 Worsening of renal function 3 1. Francis GS, et al. *Ann Int Med*. 1985;103:1-6. 2. Bayliss J, et al. *Br Heart J*. 1987; 57:17-22. 3. Mehta RL, et al. *JAMA*. 2002;288:2547-2553

VExUS

1. Beaubien-Souligny W, Rola P, Haycock K, Bouchard J, Lamarche Y, Spiegel R, Denault AY. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system. *The ultrasound journal*. 2020 Dec;12:1-2.